<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>

    <!-- Bootstrap CDN -->
    <link rel="stylesheet" href="css/bootstrap.min.css">

    <!-- Main CSS -->
    <link rel="stylesheet" href="css/style.css">

</head>

<body>

    <div class="fixedHeight">
        <div class="right_shape">
            <a href="../page11/index.html" class="cross_icon_close">
                <img src="img/cross_icon.svg" alt="">
            </a>
            <img src="img/right_silver_shape.png" style="zoom: .5;" alt="">
        </div>
        <div class="container_xxl container-xxl z_index9">
            <div class="py-4">
                <h4 class="txt_orange GothamBold mb-0">Chari et al. Optum’s EHR database, US Real-world study:</h4>
                <h3 class="txt_orange GothamBook">a retrospective, comparative efficacy analysis of PI-Rd <br> triplets used in routine care in the US<span class="h5">1</span></div></h3>
                <div class="mt-5">
                    <h6 class="GothamBlack txt_orange mb-4 pt-2 fs-12">Results:</h6>
                    <div class="mb-4 fs-11">
                        <div class="d-flex GothamBook txt_silver mb-2">
                            <div class="me-2"><img src="img/list_blue_icon.svg" alt=""></div>
                            <div>Ixazomib (NINLARO) + Rd had a longer DOT (median 12.3 months <br> vs 7.2 months for KRd), <br> with a lower risk of discontinuation compared with KRd<sup>1</sup></div>
                        </div>

                        <div class="d-flex GothamBook txt_silver mb-2">
                            <div class="me-2"><img src="img/list_blue_icon.svg" alt=""></div>
                            <div>In adjusted* analysis, TTNT was comparable for all PI-Rd triplet combinations<sup>1</sup></div>
                        </div>

                        <div class="d-flex GothamBook txt_silver mb-2">
                            <div class="me-2"><img src="img/list_blue_icon.svg" alt=""></div>
                            <div>But TTNT was significantly longer with other PI-Rd combinations vs KRd in <br> patients with intermediate/frail modified frailty score<sup>1</sup></div>
                        </div>
                    </div>
                    <div class="p12_graph_wrapper pt-3">
                        <div class="p12_graph_item">
                            <div class="w-100">
                                <div class="row">
                                    <div class="col-md-5">
                                        <div class="p12_graph_before_heading txt_blue GothamMedium text-center fs-12">Adjusted* TTNT by PI-Rd regimen in ≥2 lines of therapy1</div>
                                        <img src="img/graph_left_img_p12.png" alt="" class="w-100">
                                    </div>
                                    <div class="col-md-5">
                                        <div class="p12_graph_before_heading txt_blue GothamMedium text-center fs-12">Adjusted* TTNT by PI-Rd regimen in intermediate <br> to frail patients in ≥2 lines of therapy<sup>1</sup></div>
                                        <img src="img/graph_right_img_p12.png" alt="" class="w-100">
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
        <div style="height: 240px;"></div>
        <div class="footer_page1 bg-transparent">
            <div class="container_xxl container-xxl">
                <div class="footer_inner1 footer_inner2 w-75">
                    <p class="GothamLight fs-7">*Adjusted for the following covariates: index regimen type, modified frailty score (0 [fit], 1–2 [intermediate to frail]); prior PI and/or IMiD exposure, prior SCT, history of CVD or uncontrolled hypertension, <br>
                        history of PN, or baseline CRAB symptoms (all, yes, or no), cytogenetic risk (high, standard/unknown); ISS stage (I/II, III, unknown), PI/IMiD refractory status (PI- and/or IMiD-refractory, refractory to neither), <br>
                        months from diagnosis to start of evaluated line of therapy, refractory status to last therapy (yes or no; yes was defined as a treatment-free interval from the end of the previous line of therapy to initiation of <br>
                        index regimen of ≤60 days), time of first relapse (months from start of first line of therapy to start of second line of therapy), and year of diagnosis (2007–2011, 2012–2015, 2016–2018). CI = confidence interval; <br>
                        CVD = cardiovascular disease; DOT = duration of treatment; HR = hazard ratio; IMiD = immunomodulatory drug; ISS = International Staging System; KRd = carfilzomib + Rd; PI = proteasome inhibitor; <br>
                        PN = peripheral neuropathy; IRd = Ixazomib (NINLARO) + Rd; Rd = REVLIMID® (lenalidomide) + dexamethasone; EHR = electronic health record; SCT = stem cell transplantation; TTNT = time to next therapy; <br>
                        US = United States; VRd = bortezomib + REVLIMID® (lenalidomide) + dexamethasone</p>
                </div>
            </div>
            <div class="footer_inner_nav1 bg-transparent footer_inner_nav1_modified_reff">
                <ul class="mb-1 me-1">
                    <li>
                        <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                    </li>
                    <li>
                        <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" class="text-uppercase">pi</a>
                    </li>
                    <li>
                        <a href="#" class="text-uppercase">ref</a>
                    </li>
                </ul>
            </div>
        </div>
    </div>

</body>

</html>